Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

By S. O’Brien, F. Guilhot, R. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fischer, Andreas Hochhaus, T. Hughes and 15 more. New England Journal of Medicine, 2003

3,629 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/36e0fa03a2fa4fe3bee011e15578fba0209fb7c0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Hematology

In Rheumatology

Citations in the corpus

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, methodology): “treatment for patients with CML-CP based on data from a randomized phase III trial known as IRIS [36] that compared imatinib 400 mg daily with IFN- plus cytosine arabinoside (Ara-C) in 1106 previously untreated CML-CP patients.”
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. (2005, methodology): “Chronic phase CML patients who achieve a 1000-fold reduction in BCR-ABL transcript levels have a negligible risk of disease progression over the subsequent 12 months; this level of cytogenetic response has been achieved in 39% of patients receiving a standard dose regimen of imatinib (O’Brien et al.”
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. (2016, background): “IM treatment significantly increased the survival and quality of life for patients of all ages, particularly those in the chronic phase.(6,7) The improved survival in patients with CML is increasingly prevalent, a trend that is projected to continue during the coming decades.”
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. (2007, background): “In newly diagnosed patients with CML, imatinib is associated with a complete cytogenetic response rate of 87%, a progression rate to accelerated or blastic phase of 7%, and an estimated 5-year survival rate of 89%.(3,6)”
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, background): “It is recommended that in practice outside of clinical trials, the firstline treatment of CP CML can be any of the 3 TKIs that have been approved for this indication and are available nearly worldwide, namely imatinib (400mg once daily), nilotinib (300mg twice daily), and dasatinib (100 mg once dail”
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. (2008, methodology): “A correlation between a high-risk Sokal score and lower probability to achieve a CCyR on imatinib has previously been reported.22 The present multivariate analyses showed that both imatinib trough levels and Sokal risk group were predictive for achievement of CCyR.”
The biology of CML blast crisis. (2004, background): “For example, the complete cytogenetic response rate (CCyR) for early chronic-phase patients placed on imatinib is approximately 80%; for accelerated phase and blast crisis, the value falls to roughly 40% and 20%, respectively.(4,5)”
Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations (2011, background): “In cancer, advances in genomics and proteomics have resulted in the development of drugs such as trastuzumab (approved for the adjuvant and first-line treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer) [1] and imatinib (approved for several indications inc”